Cardinal Health Inc. stock (US14149Y1082): Insider activity in focus as shares hover around USD 200 on NYSE

Cardinal Health Inc. shares on the New York Stock Exchange have been changing hands close to the USD 200 mark in recent sessions, keeping the U.S. healthcare distributor on the radar of equity investors. According to recent market data, the CAH stock price has traded in a range around USD 196 to USD 201 in late May 2026, giving the group a market capitalization in the mid?USD 40 billion area and reflecting its position as a key player in the U.S. healthcare logistics market, as noted by sources such as Robinhood and Invezz that track NYSE-listed prices and valuation metrics as of 05/29/2026.

The company is headquartered in Dublin, Ohio in the United States and its primary listing is on the NYSE under the ticker CAH, which anchors the share firmly in the U.S. healthcare and distribution universe. The stock has been trading with a price-to-earnings ratio of just above 30 and a dividend yield of around 1.0% as of the latest available data on 05/29/2026, signaling that a portion of shareholder returns comes through regular cash distributions alongside capital gains potential. For German investors, the stock is also available on secondary venues such as Tradegate under its ISIN US14149Y1082, where it can be traded in euros in parallel to the U.S. listing.

The share price action in late May follows a period in which the company has remained active operationally and financially, with investors balancing its role as a large U.S. healthcare wholesaler and distributor against sector dynamics such as drug pricing, supply-chain costs, and hospital demand trends. Market data providers that aggregate NYSE trading show that Cardinal Health’s shares have further seen a 52-week move that took them from significantly lower levels toward the current around-USD-200 area, though exact 52-week high and low figures depend on the specific data source and time stamp used. On the liquidity side, the stock typically trades with solid daily volumes, reflecting its membership in major U.S. equity indices and the attention it receives from institutional portfolios.

The stock traded at about USD 200 on 05/29/2026 on the NYSE, according to Robinhood data for CAH as of that date, which also list a day high above USD 201 and an intraday low below USD 197, underlining modest but notable intraday volatility for a large-cap healthcare distributor. In Germany, indicative quotes on Tradegate for the same ISIN convert to a similar valuation range when adjusted for the USD/EUR exchange rate, although euro-denominated prices on that venue will naturally diverge slightly due to currency moves and local trading spreads.

As of: 05/30/2026

By the editorial team - specialized in equity coverage.

Cardinal Health Inc.: core business model

Cardinal Health generates most of its revenue by sourcing, distributing, and manufacturing pharmaceuticals and medical products for hospitals, pharmacies, and other healthcare providers, earning margins on large-volume logistics and value-added services across the healthcare supply chain.

Insider activity and ownership structure

Beyond daily share price moves, insider transactions and ownership patterns provide additional context for Cardinal Health. Data compiled by MarketBeat on insider trading activities for CAH show that company insiders have sold a cumulative 422,281 shares over the past 24 months, with an aggregate value of approximately USD 56.8 million, reflecting a steady stream of share disposals rather than large one-off blocks. The same data indicate that insiders collectively own about 0.12% of the company’s outstanding shares as of 2026, a relatively small direct ownership stake for management and board members in comparison with the large free float held by institutional and retail investors.

MarketBeat’s granular breakdown of these transactions lists several named executives among the sellers. Over the two-year period, insiders including Jason M. Hollar, Deborah Weitzman, Jessica L. Mayer, Michelle D. Greene, Ola M. Snow, Mary C. Scherer, Stephen M. Mason, and Aaron E. Alt have each realized proceeds ranging from around USD 250,000 to close to USD 30.4 million from their respective sales of CAH shares. While these figures testify to ongoing monetization of equity stakes, insider sales can occur for many reasons such as diversification or tax planning, and thus do not automatically signal a negative view of the company’s prospects. For investors monitoring governance and alignment, the relatively modest overall insider ownership share underscores the importance of understanding the role of institutional shareholders and index funds in the capital structure alongside management’s equity exposure.

Conclusion

With Cardinal Health Inc. stock trading near USD 200 on the NYSE and characterized by solid liquidity and a mid?USD 40 billion market capitalization, the company remains an important U.S. healthcare distributor watched closely by equity markets. The pattern of insider selling over the past 24 months, totaling more than 420,000 shares and about USD 56.8 million in value, adds another layer of information for investors assessing governance and alignment between management and shareholders. How these ownership trends intersect with the firm’s operating performance, sector developments, and valuation metrics will likely continue to shape sentiment around Cardinal Health’s shares over the coming quarters.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.